GnRH agonists work by overstimulating the pituitary gland until it essentially shuts down its production of reproductive hormones. They mimic a natural brain signal called gonadotropin-releasing hormone (GnRH), but instead of delivering it in the short, rhythmic pulses the body uses, they flood the system with a constant supply. This sustained stimulation initially revs up hormone production, then causes the pituitary to pull its receptors offline, cutting off the hormonal chain that drives testosterone and estrogen production.
The Normal Hormone Signal
Your hypothalamus, a small region at the base of the brain, naturally releases GnRH in bursts roughly every 60 to 90 minutes. Each pulse tells the pituitary gland to release two hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These travel through the bloodstream to the ovaries or testes, where they trigger the production of estrogen or testosterone. The pulsing pattern is critical. The pituitary needs those gaps between signals to reset and respond properly to the next one.
What Happens When You Override the Pulses
A GnRH agonist is a synthetic version of GnRH, modified to be more potent and longer-lasting than the natural hormone. When injected, it locks onto the same receptors on the pituitary and activates them, just like the real thing. But because the drug delivers continuous stimulation rather than pulses, the pituitary can’t reset between signals.
At first, this continuous activation causes a surge. LH levels can spike dramatically within hours. In one study of men receiving their first injection, average LH rose from about 7 to 38 mIU/mL within eight hours. Testosterone followed, climbing to around 589 ng/dL by day two, an increase of roughly 225 ng/dL above baseline. This initial surge is called the “flare” and typically lasts about a week.
Then the system crashes. The pituitary responds to the relentless stimulation by pulling its GnRH receptors inside the cell, a process called internalization and downregulation. With fewer receptors on the surface, the gland becomes increasingly deaf to the signal. LH drops below baseline within about seven days, and testosterone follows it down. Most patients reach suppressed levels within two to four weeks, with deeper suppression continuing over three months.
Why the Receptors Disappear
The GnRH receptors in the pituitary are unusual compared to similar receptors elsewhere in the body. They lack a structural feature (a tail on the protein) that most receptors use to quickly shut themselves off and get recycled. This means they don’t desensitize rapidly on their own the way other receptors do. Instead, under continuous agonist exposure, they slowly get pulled into the interior of the cell and broken down. The net effect is a dramatic reduction in the number of functioning receptors available on the cell surface. Without those receptors, the pituitary stops producing meaningful amounts of LH and FSH, and the ovaries or testes lose the signal they need to make sex hormones.
The Flare Period and How It’s Managed
The initial hormone surge matters most in prostate cancer treatment, where a temporary spike in testosterone can theoretically stimulate tumor growth. To block this effect, doctors sometimes prescribe a short course of an antiandrogen medication during the first few weeks. The American Urological Association specifically recommends antiandrogens only for this purpose when used alongside GnRH agonists, not as a long-term combination. In practice, most patients don’t experience clinically significant symptoms from the flare, but the precaution is standard in advanced disease.
For conditions like endometriosis, the estrogen flare is less of a clinical concern, though some people notice a brief worsening of symptoms before improvement begins.
Conditions Treated With GnRH Agonists
The core principle is the same across all uses: suppress sex hormones to starve a hormone-dependent process. The specific goals differ by condition.
- Prostate cancer: Testosterone fuels prostate cancer growth. GnRH agonists reduce testosterone to castrate levels (below 50 ng/dL), typically within about 21 days on average. Deeper suppression to below 20 ng/dL is achievable in most patients within three months. This is the cornerstone of androgen deprivation therapy for advanced disease.
- Endometriosis: Estrogen drives the growth of endometrial-like tissue outside the uterus. Suppressing estrogen shrinks these implants and reduces pain. Treatment duration is usually limited to six months because of side effects from estrogen loss.
- Uterine fibroids: These benign growths are estrogen-sensitive. GnRH agonists can shrink fibroids before surgery, making procedures less invasive.
- Precocious puberty: In children who begin puberty abnormally early, GnRH agonists pause development by suppressing LH and FSH. The primary goal is protecting adult height, since early puberty causes growth plates to close sooner. Children continue treatment until they reach the typical age of puberty, then stop the medication and development resumes normally.
How They’re Given
GnRH agonists are typically administered as depot injections, slow-release formulations that deliver medication steadily over weeks or months. Triptorelin, for example, comes in 4-week (3.75 mg), 12-week (11.25 mg), and 24-week (22.5 mg) formulations. Other common options include leuprolide and goserelin, available in similar extended-release schedules. The longer-interval injections are identical in effectiveness and simply offer more convenience, reducing the number of clinic visits from monthly to a few times per year.
Newer oral GnRH antagonists (a related but different class) work by blocking the receptor rather than overstimulating it, which avoids the initial flare entirely. These are increasingly used for endometriosis in combination with low-dose hormones.
Side Effects From Hormone Suppression
Because GnRH agonists dramatically lower sex hormones, their side effects are essentially the symptoms of hormone deficiency. In men, this means hot flashes, fatigue, reduced libido, and loss of muscle mass. In women, the experience closely mirrors menopause: hot flashes, vaginal dryness, mood changes, and sleep disruption.
Bone loss is the most serious long-term concern. In men on androgen deprivation therapy, lumbar spine bone mineral density dropped by roughly 4 to 5 percent in the first year alone. This rate of loss is significant and accelerates fracture risk over time, which is why doctors monitor bone health closely during extended treatment.
Add-Back Therapy to Reduce Side Effects
For endometriosis, a strategy called add-back therapy pairs the GnRH treatment with a small dose of hormones, just enough to protect bones and ease hot flashes without fueling endometrial growth. A common combination adds 1 mg of estradiol and 0.5 mg of norethindrone acetate daily. Clinical trials (the SPIRIT 1 and SPIRIT 2 studies) showed this approach maintained pain relief while significantly reducing hot flashes and bone density loss, allowing treatment to extend safely to 24 weeks. For higher doses of newer oral options used in severe pelvic pain, hormonal add-back is considered necessary specifically to preserve bone health.
Add-back therapy isn’t used in prostate cancer, where the entire point is to eliminate testosterone signaling as completely as possible.